The recent applications of nanotechnology in the diagnosis and treatment of common cardiovascular diseases
Vascul Pharmacol. 2023 Jul 25;152:107200. doi: 10.1016/j.vph.2023.107200. Online ahead of print.ABSTRACTAlmost a third of all fatalities may be attributed to cardiovascular disease (CVD), making it a primary cause of mortalities worldwide. Better diagnostic tools and secure, non-invasive imaging techniques are needed to offer accurate information on CVD progression. Several elements contribute to the success of CVD personalized therapy, and two of the most crucial are accurate diagnosis and early detection. The therapy options available for conditions with a pathogenesis that unfold over decades, such as CVD, are very cond...
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Feize Li Haibin Shao Guoer Zhou Bingzhu Wang Yan Xu Wenqing Liang Lin Chen Source Type: research
GYY4137, a hydrogen sulfide donor, protects against endothelial dysfunction in porcine coronary arteries exposed to myeloperoxidase and hypochlorous acid
CONCLUSIONS: MPO plus H2O2, and HOCl, impair coronary artery endothelial vasorelaxation via inhibition of NO. GYY4137 protects against endothelial dysfunction in arteries exposed to MPO plus H2O2, and HOCl. H2S donors such as GYY4137 are possible therapeutic options to control excessive MPO activity in cardiovascular diseases.PMID:37500030 | DOI:10.1016/j.vph.2023.107199 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Andrew Harper Maike Chapel Grace Hodgson Krzysztof Malinowski Imogen Yates Michael Garle Vera Ralevic Source Type: research
The recent applications of nanotechnology in the diagnosis and treatment of common cardiovascular diseases
Vascul Pharmacol. 2023 Jul 25;152:107200. doi: 10.1016/j.vph.2023.107200. Online ahead of print.ABSTRACTAlmost a third of all fatalities may be attributed to cardiovascular disease (CVD), making it a primary cause of mortalities worldwide. Better diagnostic tools and secure, non-invasive imaging techniques are needed to offer accurate information on CVD progression. Several elements contribute to the success of CVD personalized therapy, and two of the most crucial are accurate diagnosis and early detection. The therapy options available for conditions with a pathogenesis that unfold over decades, such as CVD, are very cond...
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Feize Li Haibin Shao Guoer Zhou Bingzhu Wang Yan Xu Wenqing Liang Lin Chen Source Type: research
GYY4137, a hydrogen sulfide donor, protects against endothelial dysfunction in porcine coronary arteries exposed to myeloperoxidase and hypochlorous acid
CONCLUSIONS: MPO plus H2O2, and HOCl, impair coronary artery endothelial vasorelaxation via inhibition of NO. GYY4137 protects against endothelial dysfunction in arteries exposed to MPO plus H2O2, and HOCl. H2S donors such as GYY4137 are possible therapeutic options to control excessive MPO activity in cardiovascular diseases.PMID:37500030 | DOI:10.1016/j.vph.2023.107199 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Andrew Harper Maike Chapel Grace Hodgson Krzysztof Malinowski Imogen Yates Michael Garle Vera Ralevic Source Type: research
The recent applications of nanotechnology in the diagnosis and treatment of common cardiovascular diseases
Vascul Pharmacol. 2023 Jul 25:107200. doi: 10.1016/j.vph.2023.107200. Online ahead of print.ABSTRACTAlmost a third of all fatalities may be attributed to cardiovascular disease (CVD), making it a primary cause of mortalities worldwide. Better diagnostic tools and secure, non-invasive imaging techniques are needed to offer accurate information on CVD progression. Several elements contribute to the success of CVD personalized therapy, and two of the most crucial are accurate diagnosis and early detection. The therapy options available for conditions with a pathogenesis that unfold over decades, such as CVD, are very conditio...
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Feize Li Haibin Shao Guoer Zhou Bingzhu Wang Yan Xu Wenqing Liang Lin Chen Source Type: research
GYY4137, a hydrogen sulfide donor, protects against endothelial dysfunction in porcine coronary arteries exposed to myeloperoxidase and hypochlorous acid
CONCLUSIONS: MPO plus H2O2, and HOCl, impair coronary artery endothelial vasorelaxation via inhibition of NO. GYY4137 protects against endothelial dysfunction in arteries exposed to MPO plus H2O2, and HOCl. H2S donors such as GYY4137 are possible therapeutic options to control excessive MPO activity in cardiovascular diseases.PMID:37500030 | DOI:10.1016/j.vph.2023.107199 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Andrew Harper Maike Chapel Grace Hodgson Krzysztof Malinowski Imogen Yates Michael Garle Vera Ralevic Source Type: research
The recent applications of nanotechnology in the diagnosis and treatment of common cardiovascular diseases
Vascul Pharmacol. 2023 Jul 25:107200. doi: 10.1016/j.vph.2023.107200. Online ahead of print.ABSTRACTAlmost a third of all fatalities may be attributed to cardiovascular disease (CVD), making it a primary cause of mortalities worldwide. Better diagnostic tools and secure, non-invasive imaging techniques are needed to offer accurate information on CVD progression. Several elements contribute to the success of CVD personalized therapy, and two of the most crucial are accurate diagnosis and early detection. The therapy options available for conditions with a pathogenesis that unfold over decades, such as CVD, are very conditio...
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Feize Li Haibin Shao Guoer Zhou Bingzhu Wang Yan Xu Wenqing Liang Lin Chen Source Type: research
GYY4137, a hydrogen sulfide donor, protects against endothelial dysfunction in porcine coronary arteries exposed to myeloperoxidase and hypochlorous acid
CONCLUSIONS: MPO plus H2O2, and HOCl, impair coronary artery endothelial vasorelaxation via inhibition of NO. GYY4137 protects against endothelial dysfunction in arteries exposed to MPO plus H2O2, and HOCl. H2S donors such as GYY4137 are possible therapeutic options to control excessive MPO activity in cardiovascular diseases.PMID:37500030 | DOI:10.1016/j.vph.2023.107199 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Andrew Harper Maike Chapel Grace Hodgson Krzysztof Malinowski Imogen Yates Michael Garle Vera Ralevic Source Type: research
The recent applications of nanotechnology in the diagnosis and treatment of common cardiovascular diseases
Vascul Pharmacol. 2023 Jul 25:107200. doi: 10.1016/j.vph.2023.107200. Online ahead of print.ABSTRACTAlmost a third of all fatalities may be attributed to cardiovascular disease (CVD), making it a primary cause of mortalities worldwide. Better diagnostic tools and secure, non-invasive imaging techniques are needed to offer accurate information on CVD progression. Several elements contribute to the success of CVD personalized therapy, and two of the most crucial are accurate diagnosis and early detection. The therapy options available for conditions with a pathogenesis that unfold over decades, such as CVD, are very conditio...
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Feize Li Haibin Shao Guoer Zhou Bingzhu Wang Yan Xu Wenqing Liang Lin Chen Source Type: research
GYY4137, a hydrogen sulfide donor, protects against endothelial dysfunction in porcine coronary arteries exposed to myeloperoxidase and hypochlorous acid
CONCLUSIONS: MPO plus H2O2, and HOCl, impair coronary artery endothelial vasorelaxation via inhibition of NO. GYY4137 protects against endothelial dysfunction in arteries exposed to MPO plus H2O2, and HOCl. H2S donors such as GYY4137 are possible therapeutic options to control excessive MPO activity in cardiovascular diseases.PMID:37500030 | DOI:10.1016/j.vph.2023.107199 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Andrew Harper Maike Chapel Grace Hodgson Krzysztof Malinowski Imogen Yates Michael Garle Vera Ralevic Source Type: research
The recent applications of nanotechnology in the diagnosis and treatment of common cardiovascular diseases
Vascul Pharmacol. 2023 Jul 25:107200. doi: 10.1016/j.vph.2023.107200. Online ahead of print.ABSTRACTAlmost a third of all fatalities may be attributed to cardiovascular disease (CVD), making it a primary cause of mortalities worldwide. Better diagnostic tools and secure, non-invasive imaging techniques are needed to offer accurate information on CVD progression. Several elements contribute to the success of CVD personalized therapy, and two of the most crucial are accurate diagnosis and early detection. The therapy options available for conditions with a pathogenesis that unfold over decades, such as CVD, are very conditio...
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Feize Li Haibin Shao Guoer Zhou Bingzhu Wang Yan Xu Wenqing Liang Lin Chen Source Type: research
GYY4137, a hydrogen sulfide donor, protects against endothelial dysfunction in porcine coronary arteries exposed to myeloperoxidase and hypochlorous acid
CONCLUSIONS: MPO plus H2O2, and HOCl, impair coronary artery endothelial vasorelaxation via inhibition of NO. GYY4137 protects against endothelial dysfunction in arteries exposed to MPO plus H2O2, and HOCl. H2S donors such as GYY4137 are possible therapeutic options to control excessive MPO activity in cardiovascular diseases.PMID:37500030 | DOI:10.1016/j.vph.2023.107199 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Andrew Harper Maike Chapel Grace Hodgson Krzysztof Malinowski Imogen Yates Michael Garle Vera Ralevic Source Type: research
The recent applications of nanotechnology in the diagnosis and treatment of common cardiovascular diseases
Vascul Pharmacol. 2023 Jul 25:107200. doi: 10.1016/j.vph.2023.107200. Online ahead of print.ABSTRACTAlmost a third of all fatalities may be attributed to cardiovascular disease (CVD), making it a primary cause of mortalities worldwide. Better diagnostic tools and secure, non-invasive imaging techniques are needed to offer accurate information on CVD progression. Several elements contribute to the success of CVD personalized therapy, and two of the most crucial are accurate diagnosis and early detection. The therapy options available for conditions with a pathogenesis that unfold over decades, such as CVD, are very conditio...
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Feize Li Haibin Shao Guoer Zhou Bingzhu Wang Yan Xu Wenqing Liang Lin Chen Source Type: research
GYY4137, a hydrogen sulfide donor, protects against endothelial dysfunction in porcine coronary arteries exposed to myeloperoxidase and hypochlorous acid
CONCLUSIONS: MPO plus H2O2, and HOCl, impair coronary artery endothelial vasorelaxation via inhibition of NO. GYY4137 protects against endothelial dysfunction in arteries exposed to MPO plus H2O2, and HOCl. H2S donors such as GYY4137 are possible therapeutic options to control excessive MPO activity in cardiovascular diseases.PMID:37500030 | DOI:10.1016/j.vph.2023.107199 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Andrew Harper Maike Chapel Grace Hodgson Krzysztof Malinowski Imogen Yates Michael Garle Vera Ralevic Source Type: research
Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study
CONCLUSION: Sacubitril/valsartan reduced the number of premature ventricular complexes and increased the percentage of biventricular pacing in a cohort of HFrEF patients already on optimal medical therapy. PVC reduction did not correlate with reverse left ventricular remodelling. Whether sacubitril/valsartan has any direct antiarrhythmic effects is an issue to be better explored in future studies.PMID:37467909 | DOI:10.1016/j.vph.2023.107196 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 19, 2023 Category: Drugs & Pharmacology Authors: Mauro Acquaro Laura Scelsi Beatrice Pasotti Alessandro Seganti Marcello Spolverini Alessandra Greco Sandra Schirinzi Annalisa Turco Antonio Sanzo Simone Savastano Roberto Rordorf Stefano Ghio Source Type: research
